|Source||Humanized (from mouse)|
|Other names||DCDS4501A, RG7596, polatuzumab vedotin-piiq|
|Drug class||Antibody-drug conjugate|
|Main uses||Diffuse large B-cell lymphoma|
|Side effects||Low red blood cells, low platelets, low white blood cells, diarrhea, nausea, fever|
|Typical dose||1.8 mg/kg|
|Chemical and physical data|
|Molar mass||149627.43 g·mol−1|
Polatuzumab vedotin, sold under the brand name Polivy, is a medication used to treat diffuse large B-cell lymphoma in combination with bendamustine and rituximab. It is used when other treatments have not worked. It is given by gradual injection into a vein.
Common side effects include low red blood cells, low platelets, low white blood cells, diarrhea, nausea, and fever. Other side effects may include peripheral neuropathy, infusion reaction, tumor lysis syndrome, liver problems, and infection. Use in pregnancy may harm the baby. It is a monoclonal antibody joined with monomethyl auristatin E (MMAE) that attaches to CD79b.
Polatuzumab vedotin was approved for medical use in the United States in 2019 and Europe in 2020. In the United Kingdom 140 mg costs the NHS about £11,000 as of 2021. This amount in the United States costs about 15,700 USD.
It is given as a dose of 1.8 mg/kg every 21 days for a total of six doses.
Mechanism of action
In terms of the mechanism we find that Polatuzumab vedotin sends MMAE to cancer cells.In the process the antibody binds to CD79b ( polatuzumab vedotin is internalized) we then find that MMAE is released in the cell, which in turn exerts cytotoxic effects on malignant B cells
In June 2019, polatuzumab vedotin-piiq was approved in the United States in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polatuzumab vedotin is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma.
The U.S. Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin used in combination with the chemotherapy bendamustine and a rituximab product. Further clinical trials are required to verify and describe the clinical benefit of polatuzumab vedotin.
The FDA approved polatuzumab vedotin based primarily on evidence from one clinical trial (NCT02257567) that was conducted in the United States, Canada, Europe, and Asia. Patients who participated in the trial had lymphoma that came back or did not improve after prior treatment.
The FDA granted the application of polatuzumab vedotin-piiq breakthrough therapy designation, priority review designation, and orphan drug designation. The FDA granted the approval of Polivy to Genentech.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 926. ISBN 978-0857114105.
- "Polatuzumab Vedotin-piiq Monograph for Professionals". Drugs.com. Archived from the original on 27 December 2021. Retrieved 28 October 2021.
- "Polivy". Archived from the original on 27 October 2020. Retrieved 28 October 2021.
- "Polivy Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 5 March 2020. Retrieved 23 August 2020.
- "Polivy EPAR". European Medicines Agency (EMA). 27 January 2020. Archived from the original on 27 October 2020. Retrieved 8 March 2020.
- "Polivy- polatuzumab vedotin injection, powder, lyophilized, for solution". DailyMed. 14 November 2019. Archived from the original on 22 October 2020. Retrieved 23 August 2020.
- "Polivy Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 January 2021. Retrieved 28 October 2021.
- Sawalha, Yazeed; Maddocks, Kami (8 June 2020). "Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data". OncoTargets and Therapy. 13: 5123–5133. doi:10.2147/OTT.S219449.
- "FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 10 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
- Clinical trial number NCT02257567 for "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma" at ClinicalTrials.gov
- "Drug Trials Snapshots: Polivy". U.S. Food and Drug Administration (FDA). 17 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
- "Polatuzumab vedotin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 20 October 2021. Retrieved 4 January 2021.
- "Drug Approval Package: Polivy". U.S. Food and Drug Administration (FDA). Archived from the original on 30 October 2020. Retrieved 4 January 2021.